Dr. Qing Wang

My name is Qing Wang and I'm the founder and CEO of Complete Omics, a multi-omics molecular diagnostic company. We are located in Maryland, Baltimore.

The overall mission of Complete Omics is to bring multi-omics molecular tests to human disease diagnostics and health surveillance, and we try to combine clinical genomics, clinical proteomics, and clinical metabolomics assays to find the best combination of those technologies at the lowest cost for disease diagnostic purposes.

The major applications in our company that we are working on two different directions. One is for disease screening assays. We call this Complete360. It covers most human disease, including all human cancers, and that assay is performed on human body fluid samples and it's combined with multi-omics assays.

We try to leverage the benefit of next-generation sequencing and clinical proteomics and metabolomics assays to try to provide very comprehensive, low-cost assays for the general population.

Another branch in Complete Omics is focusing on companion diagnostics, which is more closely related to therapeutics. We are working with pharmaceutical companies and research labs to try to help them develop their potential therapeutic targets. We are also helping those pharmaceutical companies to identify the patients that could be most likely benefit from their existing therapeutic drugs.

On the companion diagnostic direction, we're mainly working on neoantigen assays. Neoantigens are a truly personalized and patient-specific cancer therapeutic target that can be presented on a patient's tumor cell surfaces. So, in order to perform neoantigen assays, we already optimized a complete set of pipelines that can allow us to go to very deep level to see patient-specific neoantigens and also quantify the neoantigen levels for their copy numbers per tumor cell level. That not only provides therapeutic targets for the patients but also can evaluate the drug-ability of the targets.

As an essential part of the neoantigen assay, we need a very robust, sensitive mass spectrometry platform. The Agilent instrument provided us the most sensitive data after the initial evaluation of different vendors, and also provided us a very open-source software that could allow us to actually improve and build our own recursive optimization methods to generate all the optimized peptides within several hours for each patient.

I think the most exciting part of my work is that by developing molecular diagnostic assays, we are able to not only help for the disease diagnostics but also help patient-specific therapeutics. Next-generation sequencing and next-generation proteomics assays and the metabolomics assays are truly coming into clinical applications now.

And we believe that in the next decade we are able to bring a lot of new, exciting technologies into patient clinical care.